The Zhitong Finance App learned that on June 9, MSD (MRK.US) announced that the FDA has approved ENFLONSIA (clesrovimab-cfor) to prevent lower RSV respiratory diseases in newborns (babies born) and infants born or entering the first respiratory syncytial virus (RSV) season. ENFLONSIA is the first and only RSV prevention program that uses the same dosage for infants regardless of body weight.

Zhitongcaijing · 06/10 13:25
The Zhitong Finance App learned that on June 9, MSD (MRK.US) announced that the FDA has approved ENFLONSIA (clesrovimab-cfor) to prevent lower RSV respiratory diseases in newborns (babies born) and infants born or entering the first respiratory syncytial virus (RSV) season. ENFLONSIA is the first and only RSV prevention program that uses the same dosage for infants regardless of body weight.